|View printer-friendly version|
|Array BioPharma to Present Clinical Data at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics|
BOULDER, Colo.--(BUSINESS WIRE)--Oct. 22, 2007--Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on the ErbB-2 / EGFR inhibitor, ARRY-543, at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, Calif.
Event: 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
The posters will be available as PDFs after they are presented on Array's website: www.arraybiopharma.com.
About ARRY-543 / ErbB-2 / EGFR inhibitor
ErbB-2 and EGFR are receptor kinase targets that are over-expressed in a number of malignancies, including breast, lung, pancreas, colon and head and neck cancers.
ARRY-543, an oral, potent, selective, reversible dual inhibitor of EGFR and ErbB-2, demonstrated significant dose-related tumor growth inhibition when administered orally in preclinical models of human cancer.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at large market opportunities. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.
CONTACT: Array BioPharma Inc.